{"id":"W4384820346","doi":"10.3324/haematol.2022.282469","title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors","year":2023,"lang":"en","type":"letter","venue":"Haematologica","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Servier; AstraZeneca","keywords":"Mantle cell lymphoma; Internal medicine; Medicine; Refractory (planetary science); Oncology; Lymphoma; Overall survival; Materials science; Metallurgy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017188,0.0004027948,0.0008481013,0.0002623791,0.000574853,0.0009691669,0.0004697846,0.002497665,0.00351397],"category_scores_gemma":[0.004380456,0.0001674126,0.0004935279,0.0006978429,0.0002804641,0.0004953008,0.0001724441,0.001738568,0.001779525],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001324337,"about_ca_system_score_gemma":0.0007049462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002059514,"about_ca_topic_score_gemma":0.006009636,"domain_scores_codex":[0.9989556,0.0004639475,0.0001266911,0.00008756844,0.0002080081,0.0001580722],"domain_scores_gemma":[0.9969698,0.001560304,0.0002473371,0.0001534201,0.0006121074,0.0004571192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.04150473,0.001100424,0.04719823,0.0005400502,0.0006484159,0.01346239,0.0002269153,0.001683448,0.008029231,0.001134561,0.7686408,0.1158308],"study_design_scores_gemma":[0.01990147,0.01132688,0.1989208,0.0004975093,0.001387316,0.02585647,0.0005826499,0.003525888,0.01072025,0.006831235,0.7202988,0.0001505889],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.2893188,0.03712148,0.002516038,0.4796238,0.01308208,0.001089245,0.05714324,0.0002973624,0.119808],"genre_scores_gemma":[0.6829986,0.01052883,0.003952879,0.2181592,0.009269403,0.001035363,0.03614097,0.0001338311,0.03778088],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.00351397,"threshold_uncertainty_score":0.01175535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1030738814372394,"score_gpt":0.319489365297474,"score_spread":0.2164154838602346,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}